1Holick M (1989) Phylogenetic and evolutionary aspects of vitamin D from phytoplankton to humans. In Vertebrate Endocrinology: Fundamentals and Biomedical Implications [, editors]. San Diego: Academic Press.
2Holick MF (2003) Vitamin D: a millennium perspective. J Cell Biochem 88, 296–307.
3Dunnigan MG, Harland WA & Fyfe T (1970) Seasonal incidence and mortality of ischemic heart disease. Lancet ii, 793–797.
4Bull GM & Morton J (1975) Seasonal and short-term relationships of temperature with deaths from myocardial and cerebral infarction. Age Ageing 4, 19–31.
5Scragg R (1981) Seasonality of cardiovascular disease mortality and the possible protective effect of ultraviolet radiation. Int J Epidemiol 10, 337–341.
6Grimes DS, Hindle E & Dyer T (1996) Sunlight, cholesterol and coronary heart disease. QJM 89, 579–589.
7Rostand SG (1997) Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 30, 150–156.
8Zittermann A, Schleithoff SS & Koerfer R (2005) Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 94, 483–492.
9Caballero B (2007) The global epidemic of obesity: an overview. Epidemiol Rev 29, 1–5.
10Bray GA & Bellanger T (2006) Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 29, 109–117.
11Sarti C & Gallagher J (2006) The metabolic syndrome: prevalence, CHD risk, and treatment. J Diabetes Complications 20, 121–132.
12Parikh SJ, Edelman M, Uwaifo GI, et al. (2004) The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 89, 1196–1199.
13Wilson PW, Kannel WB, Silbershatz H, et al. (1999) Clustering of metabolic factors and coronary heart disease. Arch Intern Med 159, 1104–1109.
14Krause R, Buhring M, Hopfenmuller W, et al. (1998) Ultraviolet B and blood pressure. Lancet 352, 709–710.
15Merke J, Hofmann W, Goldschmidt D, et al. (1987) Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcif Tissue Int 41, 112–114.
16Merke J, Milde P, Lewicka S, et al. (1989) Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3: studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 83, 1903–1915.
17Scragg R, Sowers M & Bell C (2007) Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 20, 713–719.
18Jorde R, Figenschau Y, Emaus N, et al. (2010) Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension 55, 792–798.
19Holick MF (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81, 353–373.
20Li YC, Kong J, Wei M, et al. (2002) 1,25-Dihydroxyvitamin D (3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110, 229–238.
21Rostand SG & Drueke TB (1999) Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56, 383–392.
22Sambrook PN, Chen JS, March LM, et al. (2004) Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin D status, bone mass and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab 89, 5477–5481.
23Hashemipour S, Larijani B, Adibi H, et al. (2004) Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health 4, 38–44.
24Heshmat R, Mohammad K, Majdzadeh SR, et al. (2008) A multi-center study among different urban areas. Iranian J Publ Health 1, Suppl., 72–78.
26World Health Organization (1995) Physical Status: The Use and Interpretation of Anthropometry. Technical Report Series no. 854. Geneva: WHO.
27Craig CL, Marshall AL, Sjostrom M, et al. (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35, 1381–1395.
28Esfahani FH, Asghari G, Mirmiran P, et al. (2010) Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the Tehran Lipid and Glucose Study. J Epidemiol 20, 150–158.
29Azar M & Sarkisian E (1980) Food Composition Table of Iran. Tehran: National Nutrition and Food Research Institute, Shaheed Beheshti University.
31Aloia JF, Patel M, Dimaano R, et al. (2008) Vitamin D intake to attain a desired serum 25 hydroxyvitamin D concentration. Am J Clin Nutr 87, 1952–1958.
32Tishkoff DX, Nibbelink KA, Holmberg KH, et al. (2008) Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 149, 558–564.
33Giovannucci E, Liu Y, Hollis BW, et al. (2008) 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168, 1174–1180.
34Dobnig H, Pilz S, Scharnagl H, et al. (2008) Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 168, 1340–1349.
35Wang TJ, Pencina MJ, Booth SL, et al. (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117, 503–511.
36Snijder MB, Lips P, Seidell JC, et al. (2007) Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med 261, 558–565.
37Zittermann A, Frisch S, Berthold HK, et al. (2009) Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 89, 1321–1327.
38Major GC, Alarie F, Doré J, et al. (2007) Supplementation with calcium+vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr 85, 54–59.
39Pfeifer M, Begerow B, Minne HW, et al. (2001) Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86, 1633–1637.
40Schluter KD & Piper H (1998) Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 37, 34–41.
41Amann K, Tornig J, Flechtenmacher C, et al. (1995) Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH. Nephrol Dial Transplant 10, 2043–2048.
42Somjen D, Weisman Y, Kohen F, et al. (2005) 25-Hydroxyvitamin D3-1α-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111, 1666–1671.
43Schluter KD & Piper HM (1992) Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol 263, H1739–H1746.
44Perkovic V, Hewitson TD, Kelynack KJ, et al. (2003) Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res 26, 27–33.
45Andersson P, Rydberg E & Willenheimer R (2004) Primary hyperparathyroidism and heart disease – a review. Eur Heart J 25, 1776–1787.
46Garcia de la Torre N, Wass JA & Turner HE (2003) Parathyroid adenomas and cardiovascular risk. Endocr Relat Cancer 10, 309–322.
47Martin-Ventura JL, Ortego M, Esbrit P, et al. (2003) Possible role of parathyroid hormone-related protein as a proinflammatory cytokine in atherosclerosis. Stroke 34, 1783–1789.
48Foley RN, Parfrey PS & Sarnaak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32, 5 Suppl. 3, S112–S119.
49Khajehdehi P & Taheri S (2003) Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis patients: its safety in a combination with oral calcium carbonate. J Ren Nutr 13, 78–83.
50Lacour B, Basile C, Drueke T, et al. (1982) Parathyroid function and lipid metabolism in the rat. Miner Electrolyte Metab 7, 157–165.
51Chiu KC, Chu A, Go VLW, et al. (2004) Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr 79, 820–825.
52John WG, Noonan K, Mannan N, et al. (2005) Hypovitaminosis D is associated with reductions in serum apolipoprotein A-I but not with fasting lipids in British Bangladeshis. Am J Clin Nutr 82, 517–522.
53Barger-Lux MJ, Heaney RP, Lanspa SJ, et al. (1995) An investigation of sources of variation in calcium absorption efficiency. J Clin Endocrinol Metab 80, 406–411.
54Denke MA, Fox MM & Schulte MC (1993) Short-term dietary calcium fortification increases fecal saturated fat content and reduces serum lipids in men. J Nutr 123, 1047–1053.
55Reid IR (2004) Effects of calcium supplementation on circulating lipids: potential pharmacoeconomic implications. Drugs Aging 21, 7–17.
56Vaskonen T, Mervaala E, Sumuvuori V, et al. (2002) Effects of calcium and plant sterols on serum lipids in obese Zucker rats on a low-fat diet. Br J Nutr 87, 239–245.
57Van der Meer R, Welberg JW, Kuipers F, et al. (1990) Effects of supplemental dietary calcium on the intestinal association of calcium, phosphate, and bile acids. Gastroenterology 99, 1653–1659.
58Malik S (2003) Transcriptional regulation of the apolipoprotein AI gene. Front Biosci 8, d360–d368.
59Auwerx J, Bouillon R & Kesteloot H (1992) Relation between 25-hydroxyvitamin D3, apolipoprotein A-1 and high density lipoprotein cholesterol. Aterioscler Thromb 12, 671–674.
60Wehmeier K, Beers A, Haas MJ, et al. (2005) Inhibition of apolipoprotein AI gene expression by 1,25-dihydroxyvitamin D3. Biochim Biophys Acta 1737, 16–26.